Tigecycline – The First Glycylcycline to Undergo Clinical Development: An Overview of In Vitro Activity Compared to Tetracycline

References

• Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001; 65: 232–260.
   PubMed Web of Science ®Google Scholar
• Levy SB. Evolution and spread of tetracycline resistance determinants. J Antimicrob Chermother 1989; 24: 1–3.
   PubMed Web of Science ®Google Scholar
• Spear BS, Shoemaker NB, Salyers AA. Bacterial resis-tance to tetracyclines: mechanisms, transfer and clinical signifi-cance. Clin Microbiol Rev 1992; 5: 387–399.
   PubMed Web of Science ®Google Scholar
• Sum PE, Sum FW, Projan SJ. Recent developments in tetracycline antibiotics. Curr Pharm Des 1998; 4: 119–132.
   PubMed Web of Science ®Google Scholar
• Testa RT, Petersen PJ, Jacobs NL, et al. In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semi-synthetic tetracyclines. Antimicrob Agents Chemother 1993; 37: 2270–2277.
   PubMed Web of Science ®Google Scholar
• Chopra I. Glycylcyclines: third generation tetracycline antibiotics. Curr Opin Pharmacol 2001; 1: 464–469.
   PubMedGoogle Scholar
• Petersen PJ, Jacobus NV, Weiss WJ et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR - 936). Antimicrob Agents Chemother 1999; 43: 738–744.
   PubMed Web of Science ®Google Scholar
• Bradford PA. Tigecycline: a first in class glycylcycline. Clin Microbiol Newsl 2004; 26: 163–68.
   Google Scholar
• Wise R, Andrews JM. In vitro activities of two glycylcy-clines. Antimicrob Agents Chemother 1994; 38: 1096–1102.
   PubMed Web of Science ®Google Scholar
• Wexler HM, Molitoris E, Finegold SM. In vitro activities of two new glycylcyclines, N, N-dimethylglycylamido deriva-tives of minocyclines and 6-demethyl-6-deoxytetracycline, against 339 strains of anaerobic bacteria. Antimicrob Agents Chemother 1994; 38: 2513-2515.
   Google Scholar
• Eliopoulos GM, Wennersten CB, Cole G, et al. In vitro activity of two glycylcyclines against Gram positive bacteria. Antimicrob Agents Chemother 1994; 38: 534–541.
   PubMed Web of Science ®Google Scholar
• Whittington WL, Roberts MC, Hale J et al. Susceptibilities of Neisseria gonorrhoeae to the glycylcyclines. Antimicrob Agents Chemother 1995; 39: 1864–1865.
   PubMed Web of Science ®Google Scholar
• Edlund C, Nord CE. In vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline. Clin Microbiol Infect 2000; 6: 159–163.
   PubMedGoogle Scholar
• Roblin PM, Hammerschlag MR. In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis. Int J Antimicrob Agents 2000; 16: 61–63.
   PubMed Web of Science ®Google Scholar
• Hoellman DB, Pankuch GA, Jacobs MR et al. Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-sus-ceptible and -resistant pneumococci. Antimicrob Agents Chemother 2000; 44: 1085-1088.
   Google Scholar
• Goldstein EJ, Citron DM, Merriam CV et al. Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens. Antimicrob. Agents Chemother. 2000; 44: 2745–2751.
   Google Scholar
• Gales AC, Jones RN. Antimicrobial activity and spec-trum of the new glycylcycline, GAR - 936 tested against 1,203 recent clinical bacterial isolates. Diagn Microbiol Infect Dis 2000; 36: 19–36.
   PubMed Web of Science ®Google Scholar
• Biedenbach DJ, Beach ML, Jones RN. In vitro antimi-crobial activity of GAR- 936 tested against antibiotic-resistant gram positive blood stream infection isolates and strains pro-ducing extended spectrum P-lactamases. Diagn Microbiol Infect Dis 2001; 40: 173–177.
   PubMed Web of Science ®Google Scholar
• Deshpande LM, Gales AC, Jones RN. Gar-936 (9-t-butylglycylamido-minocycline) susceptibility test development for streptococci, Haemophilus influenzae, Neisseria gonor-rhoeae. Preliminary guidelines and interpretative criteria. Int J Antimicrob Agents 2001; 18: 29–35.
   PubMed Web of Science ®Google Scholar
• Heine HS, Dicks R, Andrews G. In vitro activity of ori-tavancin (LY 333328), levofloxacin, meropenem, GAR-936 and linezolid against strains of Bacillus anthracis. 41” Intersciece Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, US, 2001.
   Google Scholar
• Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma hominis, M. pneumoniae and Ureaplasma ure-alyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin and telithromycin compared to their susceptibilities to refer-ence macrolides, tetracyclines and quinolones. Antimicrob Agents Chemother 2001; 45: 2604–2608.
   Google Scholar
• Betriu C, Rodriguez-Avial I, Sanchez BA, et al. In vitro activities of tigecycline (GAR - 936) against recently isolated clinical bacteria in Spain. Antimicrob Agents Chemother 2002; 46: 892–895.
   PubMed Web of Science ®Google Scholar
• Henwood CJ, Gatward T, James D, et al. Antibiotic resistance among clinical isolates of Acinetobacter spp. in the UK and in vitro evaluation of tigecycline (GAR- 936). JAntimicrob Chemother 2002; 49: 479–487.
   PubMed Web of Science ®Google Scholar
• Betriu C, Rodriguez-Avial I, Sanchez BA, Gomez M, Picazo JJ. Comparative in vitro activities of tigecycline (GAR-938) and other antimicrobial agents against Stenotrophomonas maltophilia. J Antimicrob Chemother 2002; 50: 758–759.
   PubMed Web of Science ®Google Scholar
• Petersen PJ, Bradford PA, Weiss WJ, Murphy TM, Sum PE, Projan SJ. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant Gram-positive pathogens. Antimicrob Agents Chemother 2002; 46, 2595–2601.
   PubMed Web of Science ®Google Scholar
• Wallace RJ, Brown-Elliott BA, Crist CJ, Mann L, Wilson RW. Comparison of the in vitro activity of the glycylcy-dine tigecycline (formerly GAR-936) with those of tetracycline, minocycline and doxycycline against isolates of non tubercu-lous mycobacteria. Antimicrob Agents Chemother 2002; 46: 3164-3167.
   Google Scholar
• Rhomberg PR Jones RN. In vitro activity of 11 antimi-crobial agents, including gatifloxacin and GAR-936, tested against clinical isolates of Mycobacterium marinum. Diagn Microbial Infect Dis 2002; 42: 145–147.
   PubMed Web of Science ®Google Scholar
• Edelstein PH, Weiss WJ, Edelstein MAC. Activities of tigecycline(GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother 2003; 47: 533–540.
   PubMed Web of Science ®Google Scholar
• Milatovic D, Schmitz F-J, Verhoeff J, Flint AC. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob Agents Chemother 2003; 47: 400–404.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Homenuik K, Nichol K, et al. The glycylcy-dines. A comparative review with the tetracyclines. Drugs 2004; 64: 63–88.
   Google Scholar
• Fritsche TR, Kirby JT, Jones RN. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and Gram-positive cutaneous infections. Diagn Microbiol Infect Dis 2004; 36: 2644-2645.
   Google Scholar
• Zhang Y, Zhou L, Zhu D, et al. In vitro activities of tigecycline against clinical isolates from Shanghai, China. Diagn Microbiol Infect Dis 2004; 50: 267–281.
   PubMed Web of Science ®Google Scholar
• Boucher HN, Wennersten CB, Eliopoulos GM. In vitro activities of the glycylcycline GAR-936 against Gram positive bacteria. Antimicrob Agents Chemother 2000; 44: 2225-2229.
   Google Scholar
• CLSI. Performance standards for antimicrobial suscepti-bility testing; Fifteenth Informational Supplement. CLSI Document M100-515 (ISBN 1-56238-55619), CLSI, Wayne, Pennsylvania 19087-1898, US, 2005.
   Google Scholar